Clinical Trials Logo

Clinical Trial Summary

IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin. Injected into the muscle, incobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for treatment of various neurological conditions. This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of post-stroke spasticity of the upper limb.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00432666
Study type Interventional
Source Merz Pharmaceuticals GmbH
Contact
Status Completed
Phase Phase 3
Start date June 2006
Completion date May 2008

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05940805 - Comprehensive Protocol for Treatment of Upper Limb Spasticity in Post-stroke Hemiplegic Patients N/A
Completed NCT05382767 - Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity Phase 1
Completed NCT03131791 - Comparing the Radial Extracorporeal Shock Waves and Botulinum Toxin Injection for Spasticity N/A